Hatchtech appoints new CEO
Hatchtech Pty Ltd has appointed Dr Ross Macdonald as its Chief Executive Officer. The company has also secured additional capital, bringing total funds raised in the current round to AUD7.8 million.
The appointment of the CEO and the completion of the latest financing round, enables commencement of commercialization and ongoing preparations for Phase 3 trials for Hatchtech’s novel head lice treatment product DeOvoTM.
Dr Macdonald is presently a non-executive director of the board of Hatchtech. He has 24 years experience in the pharmaceuticals industry and was directly involved in the development and global commercialization of several successful head lice treatment products.
Dr Macdonald previously held the position of Vice President of Business Development for Sinclair Pharmaceuticals Ltd (now Sinclair IS Phama plc), a UK-based specialty pharmaceuticals company. Prior to that he was Vice President, Corporate Development for Stiefel Laboratories Inc, the largest independent dermatology company in the world and acquired by GlaxoSmithKline in 2009 for £2.25b. Other positions held include Vice President of Research & Development with FH Faulding & Co Limited (acquired in 2001 by Mayne Nickless) and Managing Director of Soltec Research Pty Ltd.
Other news from the department people
